OncoFreeze™1 AI addresses today’s respiratory motion management challenges. Building on the benefits of OncoFreeze technology, OncoFreeze AI integrates Siemens Healthineers’ proprietary deviceless waveform and anatomical algorithm technology to enable a motion management solution with a simple click of a button.
OncoFreeze AIDeviceless motion management for PET imaging
Features & Benefits
Breathe easy with OncoFreeze AI: simple, one-button, deviceless correction that reduces scan time2 and setup while enhancing patient comfort.
With OncoFreeze AI, you combine the power of deviceless waveform generation and Automated Landmarking and Parsing of Human Anatomy (ALPHA) technology to seamlessly create images virtually free of respiratory motion in the same amount of time as a conventional whole-body scan.
PET motion correction is now a reality for every patient and every scan—all with one easy press of a button.
Free of external devices
Faster, more comfortable exams
Extended FOV one-click motion correction
Expert insights
“Now, with OncoFreeze AI, we can offer better-quality scans, independent of indications.”
The University of Tennessee Graduate School of Medicine
Knoxville, Tennessee, USA
“We have OncoFreeze™ AI turned on for all patients—we have it for adults; for children; and for FDG, for PSMA, and DOTATOC/DOTATATE.”
Professor and Head of Department of Nuclear Medicine and Molecular Imaging
Lausanne, Switzerland
ALPHA technology
ALPHA technology is a unique, deep learning, artificial intelligence algorithm that detects specific anatomical landmarks. This allows for automatic identification of the zone to be corrected for respiratory motion.
Deviceless waveform
OncoFreeze AI eliminates the need for additional setup of external physiological devices both on the patient and at the scanner and acquires a respiratory waveform that will be used to generate motion-frozen or cine, PET reconstructed images.
Our deviceless waveform is a respiratory signal derived directly from the acquired raw PET list-mode data. The deviceless waveform leverages FlowMotion™ (continuous bed motion) to always know its location over the body and determine the respiratory signal for axially extended PET acquisitions.
Using a deviceless waveform can have an additional benefit because it can acquire a respiratory waveform even in the case where an external device would fail.
Expert insights
“Using OncoFreeze AI is so much more comfortable for the patients and has an impact— especially for claustrophobic and nervous patients.”
Katie Morris
Deputy Service Lead for Nuclear Medicine and PET/CT
The Royal Marsden NHS Foundation Trust
London, England
“For patients with lesions that are very close to the diaphragm, sometimes you don't really know if it's in the liver or in the lung; you may have doubts on both. OncoFreeze AI can really make a difference in cases like this.”
John O. Prior, PhD, MD, FEBNM
Professor and Head of Department of Nuclear Medicine and Molecular Imaging
Lausanne, Switzerland
Clinical Use
Clinical image review
Case 1
01Case 2
01Case 3
01OncoFreeze AI helps define lesion edge and volume definition of lung tumor base compared to non-gated PET
Examination Protocol
Biograph™ Horizon
8.7 mCi (321 MBq) 18F FDG
CT: 100 kV, 20 ref mAs
PET: 1.1 mm/s head-to-pelvis and 1.3 mm/s extremities FlowMotion continuous bed motion, 180 x 180 matrix
OncoFreeze AI shows similar image quality, motion management, and SUV results compared to respiratory gating device
Examination protocol
Biograph Vision™3
2.6 mCi (97 MBq) 18F FDG
CT: 100 kV, 13 ref mAs
PET: 1.3 mm/s FlowMotion continuous bed motion, 440 x 440 matrix
OncoFreeze AI provides sharp visualization of small lung nodules using deviceless respiratory motion management
Examination Protocol
Biograph Vision
6.3 mCi (234 MBq) 18F FDG
CT: 100 kV, 20 ref mAs
PET: 1.1 mm/s FlowMotion continuous bed motion, 440 x 440 matrix
OncoFreeze AI helps define lesion edge and volume definition of lung tumor base compared to non-gated PET
Examination Protocol
Biograph™ Horizon
8.7 mCi (321 MBq) 18F FDG
CT: 100 kV, 20 ref mAs
PET: 1.1 mm/s head-to-pelvis and 1.3 mm/s extremities FlowMotion continuous bed motion, 180 x 180 matrix
OncoFreeze AI shows similar image quality, motion management, and SUV results compared to respiratory gating device
Examination protocol
Biograph Vision™3
2.6 mCi (97 MBq) 18F FDG
CT: 100 kV, 13 ref mAs
PET: 1.3 mm/s FlowMotion continuous bed motion, 440 x 440 matrix
OncoFreeze AI provides sharp visualization of small lung nodules using deviceless respiratory motion management
Examination Protocol
Biograph Vision
6.3 mCi (234 MBq) 18F FDG
CT: 100 kV, 20 ref mAs
PET: 1.1 mm/s FlowMotion continuous bed motion, 440 x 440 matrix
OncoFreeze AI helps define lesion edge and volume definition of lung tumor base compared to non-gated PET
Examination Protocol
Biograph™ Horizon
8.7 mCi (321 MBq) 18F FDG
CT: 100 kV, 20 ref mAs
PET: 1.1 mm/s head-to-pelvis and 1.3 mm/s extremities FlowMotion continuous bed motion, 180 x 180 matrix
OncoFreeze and OncoFreeze AI
- OncoFreeze AI benefits from its predecessor, OncoFreeze.
- Both solutions support the generation of motion-frozen images without any additional scan time, however OncoFreeze AI acquires a deviceless signal.
- Using the optimal gate, the gated image that demonstrates the most quiescent point of the respiratory cycle, OncoFreeze generates a motion frozen image using 100% of the counts from a static image.
Technical Specifications
General Requirements
System
- Biograph Vision™ PET/CT
- Biograph™ mCT PET/CT
- Biograph Horizon PET/CT
Minimum Software Version
- Biograph Horizon must run SW PETsyngo VJ30 or higher1
- Biograph mCT and Vision must run SW PETsyngo VG80 or higher1
Other
Please Note: Additional technical pre-requisites may apply. Upon receiving your request, your local Siemens representative will clarify whether your system meets the requirements.
The features herein are not commercially available in all countries. Its future availability cannot be guaranteed. Please contact your local Siemens Healthineers organization for further details.
Compared to conventional gated scan.
Biograph Vision is not commercially available in all countries. Due to regulatory reasons, its future availability cannot be guaranteed. Please contact your local Siemens Healthineers organization for further details.
The statements by Siemens Healthineers customers described herein are based on results that were achieved in the customer's unique setting. Because there is no "typical" hospital or laboratory and many variables exist (eg, hospital size, samples mix, case mix, level of IT, and/or automation adoption) there can be no guarantee that other customers will achieve the same results.